Quick Answer
Zymeworks Inc. reported R&D Expense of $143.62 million for fiscal year 2023.
Zymeworks Inc. R&D Expense — Annual History
| Fiscal Year | R&D Expense | YoY Change |
|---|---|---|
| 2023 | $143.62M | -31.1% |
| 2022 | $208.60M | +4.4% |
| 2021 | $199.75M | +16.7% |
| 2020 | $171.20M | — |
Quarterly R&D Expense
| Quarter Ending | R&D Expense | YoY | QoQ |
|---|---|---|---|
| March 31, 2024 | $32.04M | -30.2% | -2.2% |
| September 30, 2023 | $32.77M | -11.7% | -16.8% |
| June 30, 2023 | $39.41M | -29.7% | -14.2% |
| March 31, 2023 | $45.91M | -26.6% | +23.8% |
| September 30, 2022 | $37.10M | -25.6% | -33.8% |
| June 30, 2022 | $56.02M | — | -10.4% |
| March 31, 2022 | $62.51M | — | +25.3% |
| September 30, 2021 | $49.89M | — | — |
- Zymeworks Inc. showed a decrease of -31.1% in R&D Expense compared to the prior fiscal year.
- Over the 2020–2023 period, Zymeworks Inc.’s r&d expense has declined by 16.1% (from $171.20 million to $143.62 million).
- The most recent figure is from Zymeworks Inc.’s fiscal year 2023 report (Form 10-K), filed with the SEC on March 6, 2024.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: